Fareston (toremifene) for metastatic breast cancer

July 1997

Schering will soon introduce Fareston (toremifene) for metastatic breast cancer.

It's the first estrogen antagonist to hit the market since Nolvadex (tamoxifen) came out 20 years ago.

Fareston is structurally very similar to Nolvadex.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote